Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai’s NMOSD Drug Enspryng Now Available in Taiwan
October 3, 2023
- Izumi Yoshida Named Japan President of CSL Behring
October 2, 2023
- GSK, Kyushu University Forge Oncology Partnership
October 2, 2023
- Takeda Seeks Japan Nod for Hutchmed’s Colorectal Cancer Drug
October 2, 2023
- Pfizer Japan Files New Dosage Forms for XBB.1.5 COVID Vaccine
October 2, 2023
- Medipal/JCR to Pair Up for Mucopolysaccharidosis Type IIIB Drug
September 29, 2023
- Eisai/Tokio Marine Launch Dementia Insurance Ahead of Leqembi Rollout
September 29, 2023
- Acoalan Misses Mark in PIII Preeclampsia Trial: Kyowa Kirin
September 29, 2023
- Pioneer Director Atsushi Kitamura Picked as Astellas CFO
September 29, 2023
- Entyvio Subcutaneous Form Approved in US: Takeda
September 29, 2023
- Shionogi’s Fragile X Syndrome Drug Gets Rare Pediatric Disease Tag in US
September 29, 2023
- Lilly Japan to Build New Manufacturing Facility, Eyes Mounjaro Supply Boost
September 28, 2023
- Mundipharma Files Anesthetic Med Anerem for New Indication in Japan
September 28, 2023
- Sawai’s Revlimid Generic Gets MDS Nod; December Listing Eyed
September 28, 2023
- Lucentis, Rituxan Biosimilars Win Label Expansions
September 28, 2023
- Pfizer Rolls Out Alopecia Areata Drug Litfulo in Japan
September 28, 2023
- Ono, Adimab Join Hands to Discover Antibody Drugs for Cancer
September 28, 2023
- Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
- Lilly’s Alzheimer’s Therapy Filed in Japan, Approval Eyed in 2024
September 27, 2023
- LEO Pharma’s Eczema Drug Adtralza Now Available in Japan
September 27, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…